PD-L1 expressing circulating tumor cells to predict survival in patients with advanced hepatocellular carcinoma treated with immunotherapy

Kaloyan Radushev; Michael Karin; Daniel Rössler; Elif Öcal; Katrin Böttcher; Clint Gray; Julia Schneider; Stefan Enßle; Moritz Wildgruber; Max Seidensticker; Ignazio Piseddu; Andreas Geier; Julia Mayerle; Jens Ricke; Enrico N. De Toni; Ursula Ehmer; Florian P. Reiter; Najib Ben Khaled; Marianna Alunni‐Fabbroni

doi:10.1055/s-0045-1806884

Related publications

Article2020

Mutations in circulating tumor DNA predict primary resistance to systemic therapies in patients with advanced hepatocellular carcinoma

Johann von Felden, Amanda J. Craig, Ismaïl Labgaa, Teresa García‐Lezana, Delia D’Avola, Amon Asgharpour, Douglas T. Dieterich, Antoinette Bonaccorso, Miguel Torres‐Martín, Daniela Sia, Max W. Sung, Parissa Tabrizian, Myron Schwartz, Josep M. Llovet, Augusto Villanueva

Journal of Hepatology

Article2020

Scientific Rationale for Combined Immunotherapy with PD-1/PD-L1 Antibodies and VEGF Inhibitors in Advanced Hepatocellular Carcinoma

Masatoshi Kudo

Article2025

Clinical Feasibility of Circulating Tumor DNA in Patients with Advanced Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab

Sohyun Hwang, Dong Jun Shin, Beodeul Kang, Haeyoun Kang, Sung Hwan Lee, Jung Sun Kim, Je‐Gun Joung, Suyog Jain, Steven R. Olsen, Lars Becker, Richard S. Finn, Josep M. Llovet, Gwangil Kim, Chan Kim, Hong Jae Chon

Article2020

Mutations in circulating tumor DNA predict primary resistance to systemic therapies in advanced hepatocellular carcinoma

Johann von Felden, Amanda J. Craig, Teresa García‐Lezana, Ismaïl Labgaa, Philipp K. Haber, Delia D’Avola, Amon Asgharpour, Douglas T. Dieterich, Antoinette Bonaccorso, Miguel Torres‐Martín, Daniela Sia, Max W. Sung, Parissa Tabrizian, Myron Schwartz, Josep M. Llovet, Augusto Villanueva

Oncogene

Article2022

Higher proportions of CD39+ tumor-resident cytotoxic T cells predict recurrence-free survival in patients with stage III melanoma treated with adjuvant immunotherapy

Grace H. Attrill, C. Owen, Tasnia Ahmed, Ismael A. Vergara, Andrew J. Colebatch, Jordan W. Conway, Kazi Nahar, John F. Thompson, Inês Pires da Silva, Matteo S. Carlino, Alexander M. Menzies, Serigne Lo, Umaimainthan Palendira, Richard A Scolyer, Georgina V. Long, James S. Wilmott

PD-L1 expressing circulating tumor cells to predict survival in patients with advanced hepatocellular carcinoma treated with immunotherapy

Discussion(0)

Related publications

Mutations in circulating tumor DNA predict primary resistance to systemic therapies in patients with advanced hepatocellular carcinoma

Scientific Rationale for Combined Immunotherapy with PD-1/PD-L1 Antibodies and VEGF Inhibitors in Advanced Hepatocellular Carcinoma

Clinical Feasibility of Circulating Tumor DNA in Patients with Advanced Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab

Mutations in circulating tumor DNA predict primary resistance to systemic therapies in advanced hepatocellular carcinoma

Higher proportions of CD39+ tumor-resident cytotoxic T cells predict recurrence-free survival in patients with stage III melanoma treated with adjuvant immunotherapy